Humanwell Healthcare (600079.SH): Injection of Fentanyl Hydrochloride has obtained market approval from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany.
ST Yinfu (600079.SH) announced that its controlling subsidiary, Yichang Yinfu Pharmaceutical Co., Ltd. (referred to as "Yichang Yinfu", of which the company holds 80% equity), recently received the approval letter for the listing permit of injection of Remifentanil Hydrochloride issued by the Federal Institute for Drugs and Medical Devices (BfArM) of Germany.
Humanwell Healthcare (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu", in which the company holds 80% of the equity) recently received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the market authorization of injectable sufentanil hydrochloride.
Injectable sufentanil hydrochloride has been granted market approval by the German Federal Institute for Drugs and Medical Devices (BfArM), with approved indications including: 1) analgesia during induction and/or maintenance of general anesthesia; 2) analgesia for mechanically ventilated critically ill patients aged 18 and above.
Related Articles
Guotai Haitong: The foundation of the gold bull market is still in place. Short-term adjustments and fluctuations can still provide good allocation opportunities.
CITIC SEC: Price differentiation in commodities continues in Q2 2026, remains optimistic about the performance of chemical products.
NIO (09866) Li Bin: Standardization of battery cells and normalization of chips will provide the industry with an opportunity to reduce costs by over 100 billion yuan.
Guotai Haitong: The foundation of the gold bull market is still in place. Short-term adjustments and fluctuations can still provide good allocation opportunities.
CITIC SEC: Price differentiation in commodities continues in Q2 2026, remains optimistic about the performance of chemical products.
NIO (09866) Li Bin: Standardization of battery cells and normalization of chips will provide the industry with an opportunity to reduce costs by over 100 billion yuan.
RECOMMEND
